Literature DB >> 17786503

Is digital rectal examination still necessary in the early detection of prostate cancer?

M R Quinlan1, S Teahan, D Mulvin, D M Quinlan.   

Abstract

BACKGROUND: PSA measurement is important in prostate cancer detection. However, applying cut-off values of >4 ng/ml as indication for biopsy misses 20-30% of tumours. AIMS: To determine the number of patients with prostate cancer and normal age-related PSA, referred for TRUS biopsy due to abnormal DRE alone.
METHODS: We reviewed patients referred for biopsy over 12 months. Indication for biopsy included abnormal PSA, abnormal DRE, or both.
RESULTS: Four-hundred and sixty-five (465) TRUS biopsies were performed, 209 were positive. Of the 183 (183/209) positive on whom complete data were available, 4 (2.2%) had a normal age-related PSA but an abnormal DRE.
CONCLUSIONS: Metastatic prostate cancer remains incurable. Therefore detection of organ-confined and potentially curable disease, is crucial. Though PSA has led to earlier detection, this study emphasises the importance of clinical examination, illustrating a normal PSA cannot eliminate the possibility of cancer. DRE and PSA should be interpreted as being collaborative, not competitive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786503     DOI: 10.1007/s11845-007-0018-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  12 in total

1.  Complexed PSA: the newest advance in PSA testing.

Authors:  M K Brawer
Journal:  Urology       Date:  1999-07       Impact factor: 2.649

Review 2.  PSA and early prostate cancer detection: the importance of age-specific reference ranges.

Authors:  J E Oesterling
Journal:  Can J Oncol       Date:  1994-11

3.  Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?

Authors:  Joe Philip; Subhajit Dutta Roy; Mohammed Ballal; Christopher S Foster; Pradip Javlé
Journal:  BJU Int       Date:  2005-05       Impact factor: 5.588

4.  Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.

Authors:  T Mäkinen; T L Tammela; M Hakama; U H Stenman; S Rannikko; J Aro; H Juusela; L Määttänen; A Auvinen
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

5.  Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997.

Authors:  R O Roberts; E J Bergstralh; M M Lieber; S J Jacobsen
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

6.  Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.

Authors:  B Candas; L Cusan; J L Gomez; P Diamond; R E Suburu; J Lévesque; G Brousseau; A Bélanger; F Labrie
Journal:  Prostate       Date:  2000-09-15       Impact factor: 4.104

7.  Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.

Authors:  Tze Kiat Ng; Despina Vasilareas; Andrew J Mitterdorfer; Peter O Maher; Andre Lalak
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

8.  Metastatic prostate cancer with normal level of serum prostate-specific antigen.

Authors:  R Nishio; Y Furuya; O Nagakawa; H Fuse
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

9.  Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml.

Authors:  J W Colberg; D S Smith; W J Catalona
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  3 in total

1.  Abdominal and back pain in a 65-year-old patient with metastatic prostate cancer.

Authors:  Theodore L Johnson
Journal:  J Chiropr Med       Date:  2010-03

2.  Novel predictive tools for Irish radical prostatectomy pathological outcomes: development and validation.

Authors:  D M Fanning; F Yue; J M Fitzpatrick; R W G Watson
Journal:  Ir J Med Sci       Date:  2009-07-14       Impact factor: 1.568

3.  The value of appropriate assessment prior to specialist referral in men with prostatic symptoms.

Authors:  M R Quinlan; B J O'Daly; M F O'Brien; S Gardner; G Lennon; D W Mulvin; D M Quinlan
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.